tobramycin
therapy
pulmonary
infections
patients
cystic
fibrosis
six
patients
exacerbations
chronic
pulmonary
infections
association
cystic
fibrosis
treated
intramuscular
tobramycin
mg
kg
day
divided
doses
eight
treatment
courses
lasted
days
mean
serum
levels
microg
ml
hours
microg
ml
hours
dose
tobramycin
mean
tobramycin
concentration
sputum
microg
ml
eighty
two
percent
pathogenic
bacterial
isolates
sputum
either
pseudomonas
sp
staphylococcus
aureus
ninety
seven
percent
pseudomonas
sp
percent
staphylococcus
aureus
inhibited
microg
tobramycin
per
ml
organism
isolated
therapy
observed
become
resistant
tobramycin
although
occasions
colonization
new
resistant
gram
negative
bacilli
occurred
courses
therapy
patients
showed
clinical
improvement
elimination
bacterial
pathogens
sputum
rarely
achieved
necessary
produce
clinical
improvement
colonization
resistant
flora
uncommon
finding
tobramycin
side
effects
limited
local
discomfort
injection
site
nausea
vomiting
